FDA/NIAID discussion of DDC
FDA Commissioner Young and top officials from Center for Biologics Evaluation and Research met March 2 with National Institute of Allergy & Infectious Diseases (NIAID) AIDS Program Director Daniel Hoth, PhD, and representatives from Hoffmann-LaRoche to discuss progress of AIDS drug dideoxycytidine (DDC). The Roche drug is in Phase II trials at NIAID and the National Cancer Institute (NCI). NIAID trials at 11 centers involve a DDC/AZT combination, while the NCI trial is looking at alternating administration of the two drugs. Feb. 1 Annals of Internal Medicine study reports that DDC decreased serum p24 antigen in most of 61 AIDS or ARC patients enrolled in Phase I/II dose-ranging test.
You may also be interested in...
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.
After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.